Expert team, headed by Jayadeva Institute of Cardiovascular Sciences & Research head, has instead said that vaccine has shown to be ‘protective’ against cardiac events.
Hyderabad-based vaccine maker says not including ICMR in original patent application for Covaxin was ‘inadvertent error’ & ‘confidential agreement between them was not accessible’.
Study, which said nearly 30 percent of Covaxin recipients suffered from one or other side-effects, is 'misleading', says ICMR head. Journal & authors threatened with legal action.
Medical news site STAT had cited internal documents to allege that Bharat Biotech had taken ‘questionable’ steps under political pressure to speed up development of Covaxin.
The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.
Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.
Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.
Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.
ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.
IAF is firming up plans to revamp airlift capabilities with medium transport aircraft that will be assembled in India & serve as its main workhorse. Embraer is leading contender as of now.
This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.
COMMENTS